TaiMed Biologics (4147): Kapitalflussrechnung
| Preis (11.09.2026) | 52W Hoch | 52W Tief |
| 59,8 Dollar (TWD) | 78 Dollar (TWD) | 47 Dollar (TWD) |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| 180 Dollar (TWD) | - | - | - | - | - |
| #Shares | Short [%] | Short Ratio |
| 270.702.425 | - | - |
Kennzahl in 1000 TWD | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Umsatz | 611.350 | 610.162 | 491.777 | 563.008 | 413.442 | 722.485 | 704.504 | 241.041 | 8.436 | 2.076 | 135 | 319 | 137 |
Cashflow aus operativer Geschäftstätigkeit | 191.144 | -379.552 | -25.601 | -605.210 | -211.275 | -201.936 | -655.314 | -522.856 | -516.483 | -172.295 | - | - | - |
▸ Operative Cashflow Marge | 31,27% | -62,21% | -5,21% | -107,5% | -51,1% | -27,95% | -93,02% | -216,92% | -6.122,37% | -8.299,37% | -% | -% | -% |
Investitionsausgaben (CapEx) | 22.768 | 19.352 | 6.152 | 3.556 | 9.687 | 53.614 | 121.542 | 846.382 | 278.114 | 9.983 | 192 | 981 | 1.178 |
Cashflow aus Investitionstätigkeit | - | - | - | 106.115 | 190.920 | -109.163 | 366.712 | -684.247 | 212.139 | 243.367 | - | - | - |
Cashflow aus Finanzierungstätigkeit | - | - | - | 208.382 | 2.787 | 536.035 | 57.922 | 93.535 | 18.919 | 60.006 | - | 690.000 | - |
Freier Cashflow | 168.376 | -398.904 | -31.753 | -608.766 | -220.962 | -255.550 | -776.856 | -1.369.238 | -794.597 | -182.278 | -192 | -981 | -1.178 |
▸ Freie Cashflow Marge | 27,54% | -65,38% | -6,46% | -108,13% | -53,44% | -35,37% | -110,27% | -568,05% | -9.419,12% | -8.780,25% | -142,22% | -307,52% | -859,85% |
Ausgeschüttete Dividenden | - | - | - | - | - | - | - | - | - | - | - | - | - |
Neuausgabe und Rückkäufe von Stammaktien | - | - | - | - | - | - | - | - | - | - | - | - | - |
Kennzahlen dieser Seite im Lexikon
Weitere Informationen findest du im Takani-Lexikon.